ENLV · Enlivex Ltd.
$2.25
+0.01 (+0.45%)
At close · Jul 29
Market Cap
$37.87M
Shares
16.83M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.25
Open$2.29
Day$2.00–2.32
52W$0.43–7.44
Avg vol 30d447K
Short int26K · 0.2% float · 1.0d
Short vol36%
Last earningsMar 25, 2026
DataJan 2020–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+89%
above
Price vs 50-day avg
+25%
above
RSI (14)
43
neutral
MACD trend
Negative
52-week position
26%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+288%
trailing
6-month return
+106%
trailing
YTD return
+220%
this year
Relative strength
+100%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $1 — 50d above 200d
Institutional flow
Flat
3 of 35 funds reported for Jun 30 · net 0 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.16% of float · ▼ -98.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
35 holders — near 3-yr high, broad support
Squeeze score
39
low risk · 0–100
Fundamentals
EPS growth
+3590%
Y/Y
Free cash flow
$-10.5M
Balance sheet
$1.9M
net cash
Quant / Vol
risk profile
Volatility
1333%
annualized · 1-yr
Max drawdown
−74%
past year
ATR
28.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+89%
Bullish
Price vs 50-day avg
+25%
Bullish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
26%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $1 — 50d above 200d
Institutional flow
Flat
3 of 35 funds reported for Jun 30 · net 0 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.16% of float · ▼ -98.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
35 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $0
Now $2 · 26%
52-wk high $7
vs 200-day avg +89%
vs 50-day avg +25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENLV
this stock
Enlivex Ltd.
|
$37.87M | +220.1% | — | — | 0.2% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +6.6% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENLV | -50.9% | +287.9% | +106.4% | +309.1% | +220.1% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -48.5% | +290.3% | +100.1% | +311.4% | +213.1% |